跳至主要内容
临床试验/NCT02175940
NCT02175940已完成不适用

Effect of Intravitreal Ranibizumab Injection on Aqueous Humor Concentrations of Vascular Endothelial Growth Factor and Pigment Epithelium-derived Factor in Patients With Myopic Choroidal Neovascularization.

Università degli Studi di Brescia1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2013年7月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
40
试验地点
1
主要终点
vascular endothelial growth factor (VEGF) aqueous levels

研究概览

简要总结

This was a prospective, case-control study investigating aqueous levels of VEGF and PEDF in eyes with mCNV treated with IVB.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • pathologic myopia, defined as spherical equivalent >6 diopters and axial length >26 mm
  • posterior pole myopic retinal changes (posterior staphyloma, chorioretinal atrophy, papillary crescent);
  • fluorescein angiography, indocyanine green angiography and optical coherence tomography detection of the subfoveal or juxtafoveal choroidal neovascularization
  • clear ocular media;

排除标准

  • previous treatment for choroidal neovascularization, including the previous intravitreal drug injection or PDT
  • presence of other maculopathy as diabetic retinopathy or retinal vascular occlusion
  • history of recent myocardial infarction or other thromboembolic events
  • ongoing uncontrolled hypertension or glaucoma
  • refractive media opacities
  • previous eye surgery

结局指标

主要结局

vascular endothelial growth factor (VEGF) aqueous levels

时间窗: 2 months

VEGF aqueous levels before and after intravitreal ranibizumab

pigment epithelium-derived factor (PEDF) aqueous levels

时间窗: 2 months

PEDF aqueous levels before and after intravitreal ranibizumab

次要结局

  • best-corrected visual acuity(2 months)
  • central retinal thickness(2 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Andrea Russo

MD, PhD Researcher

Università degli Studi di Brescia

研究点 (1)

Loading locations...

相似试验

VEGF and PEDF in Patients With Myopic Choroidal... | 临床试验